We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · December 07, 2021

Outcomes of Durvalumab With Platinum–Pemetrexed in the Management of Unresectable Pleural Mesothelioma

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Nat. Med. 2021 Nov 01;27(11)1910-1920, PM Forde, V Anagnostou, Z Sun, SE Dahlberg, HL Kindler, N Niknafs, T Purcell, R Santana-Davila, AZ Dudek, H Borghaei, M Lanis, Z Belcaid, KN Smith, A Balan, JR White, C Cherry, IK Ashok Sivakumar, XM Shao, HY Chan, D Singh, S Thapa, PB Illei, DM Pardoll, R Karchin, VE Velculescu, JR Brahmer, SS Ramalingam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading